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A B S T R A C T
Serum thyreoglobulin (Tg) and whole body scintigraphy (I-131 WBS) have been used to detect recurrent and metastatic
thyroid cancers postoperatively. However, discordant results of Tg measurement and 131I WBS have been reported. Nega-
tive 131I WBS and a positive Tg test are usually found, but less common occurrence of positive 131I WBS and a negative Tg
test has also been demonstrated in a small but significant number of cases. Therefore, the aim of the study was to retro-
spectively analyse patients with positive 131I WBS after total thyreoidectomy and again 1 year after the radioactive io-
dine. There were 52 patients included in the study. Four weeks after surgery, during which thyroid hormone treatment
was not introduced, each patient received an ablative dose of 131I. The evaluation of the WBS was qualitative and consid-
ered positive if thyroid remnant, lymphatic node or metastasis were detected. WBS and serum Tg was measured 12
months after 131I ablation with thyroid hormone suppression. We considered positive any Tg level above the sensitivity
values and negative if lower than this level. Tg levels were related to the existence of a positive scan or a negative one. In
our 52 WBS positive patients concordant positive Tg levels were observed in 42 patients while in 10 patients we found a
negative Tg levels after the surgery. After 1-year follow-up, out of initially 42 concordant patients 8 patients showed re-
maining concordant positive Tg and WBS values. Discordant results were observed in 13 patients (4 patients were Tg-
and WBS+ while 9 patients were Tg+ and WBS-). In the majority of patients (50%) remained with concordant results
but changed from Tg+ and WBS+ to Tg- and WBS-. Diagnostic WBS is an additional valuable tool, besides Tg levels,
in the follow up of patients after total thyreoidectomy.
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Introduction
The predominant method for treatment of differenti-
ated thyroid carcinoma (DTC) is total or near-total thy-
roidectomy followed by 131I remnant ablation and thyroid
hormone suppression of thyroid-stimulating hormone
(TSH).
Local recurrences and distant metastases are not seen
frequently, particularly during the first years of follow-
-up, but sometimes occur many years later, with the over-
all survival decline to 40% when distant metastases are
present1. Therefore, long-term monitoring of DTC recur-
rence and metastases is essential throughout the pa-
tient’s life. Generally, 2 »markers« of thyroglobulin (Tg)
and 131I whole-body scanning (WBS), when used at the
same time, offer the best possibilities in the follow-up of
patients with DTC2.
The concentration of circulating Tg can increase sub-
stantially due to follicular destruction through inflam-
mation or haemorrhage, as well as through rapid disor-
dered growth of thyroid tissue, as may be observed in
Graves’ disease or follicular cell-derived neoplasms. Se-
rum Tg concentrations were found to be increased in a
range of thyroid disorders, most prominently in advan-
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ced thyroid carcinoma3,4. However, substantial overlap
was found between levels observed in benign thyroid dis-
orders and those observed in tumor patients. Moreover,
many patients with relatively small thyroid carcinomas
had serum Tg concentrations that fell within the range
of values found in healthy individuals. Tg was found to
be useful for detecting residual or recurrent disease in
patients with very small, or absent, thyroid remnants.
Two key changes in medical practice enabled this obser-
vation to be translated into the routine serum Tg moni-
toring of virtually all thyroid cancer patients that has be-
come the de facto standard of care to date.
Serum Tg levels during thyroid hormone withdrawal
(Tg-off) is usually correlated with the results of diagnos-
tic WBS (WBS). Undetectable Tg levels with negative
WBS (WBS-) suggest complete remission, whereas de-
tectable or elevated Tg concentrations are associated
with the presence of 131I uptake in local or distant meta-
stases5. However, discordant results of Tg measurement
and 131I WBS have been reported. Negative 131I DWBS
and a positive Tg test (WBS- Tg+) were found in most of
these cases6-8. The uncommon occurrence of positive 131I
WBS and a negative Tg test (WBS+ Tg-) has also been
demonstrated in a small but significant number of ca-
ses9,10.
Only thyroid follicular cells produce Tg. Therefore, if
all normal and malignant thyroid tissue is successfully
ablated, any Tg that is detected subsequently in a patient
with DTC can only be the product of recurrent malig-
nancy. This concept led to the initial studies that indi-
cated the usefulness of isolated and serial serum Tg de-
terminations as a marker for DTC and as an indicator of
the effectiveness of surgery and 131I therapy11. In pa-
tients with DTC, the Tg level depends on the capacity of
the tumor to respond to endogenous or exogenous TSH
stimulation, the ability of the tumor to synthesize and re-
lease immunologically active Tg, the amount of thyroid
tissue remnant, and the tumor size12.
Materials
Patients
We retrospectively evaluated 65 patients with differ-
entiated thyroid carcinoma who had undergone total
thyroidectomy for differentiated thyroid carcinoma and
had been subsequently referred to the Clinic of Nuclear
Medicine for 131I ablation during 2008-2010. We excluded
patients with known metastasis at the moment of diag-
nosis, those with negative Tg and positive Tg antibodies,
patients with TSH under 30 mU/mL and those with in-
complete thyreidectomy or soft tissue infiltration. There-
fore, 52 patients were included in the study correspond-
ing to 42 women and 10 males. All the body scans were
included for their valuation and simultaneous determi-
nation of Tg and Tg antibodies with TSH ?30mU/mL.
Methods
All patients were given oral information of the study
procedures to be carried out at the Clinic for Nuclear
medicine at the Clinical Center University of Sarajevo.
Informed consent was obtained from all the patients in-
cluded in the study.
Four weeks after surgery, during which thyroid hor-
mone treatment was not introduced, each patient re-
ceived an ablative dose of 131I. 131I was administered to
the patients fasting 8 h. The treatment dose was based
on the following criteria: patients with tumor restricted
to the thyroid gland and no lymph node involvement re-
ceived 3.7 GBq (100 mCi); patients with lymph node in-
volvement or extrathyroidal invasion received 4.44 GBq
(120 mCi); patients with evidence of distant metastasis
received 5.55 GBq (150 mCi). Just before 131I ablation
therapy, the level of thyroid stimulating hormone (abla-
tion-TSH) was above 30 _U/mL, and the serum Tg level
(ablation-Tg) was measured. A postablation 131I WBS
was performed 3 to 5 days after the administration of
131I.
Images were obtained after 48-72 h, and if necessary
after 5 days. The evaluation of the WBS was qualitative,
a scan was considered positive when increased tracer ac-
tivity appeared and did not correspond to physiological
elimination; therefore the scan that only demonstrated
neck activity was also considered positive image.
Tg was analysed by means of radioimmunoassay with
sensitivity in our laboratory at <0.1 ng/mL. The serum
Tg was measured 12 months after 131I ablation with thy-
roid hormone suppression. Ablation success was defined
as an undetectable level of Tg 12 months after ablation
therapy.
We considered positive any Tg level above the sensi-
tivity values and negative if lower than this level. Pa-
tients with positive anti-Tg antibodies were excluded
only if Tg negative. All patients with a positive scan were
surgically treated if indicated, but if only neck remnants
appeared, a new therapeutic 131I dose was given in order
to obtain total elimination of functioning thyroid tissue.
Tg levels were related to the existence of a positive
scan (thyroid remnants-lymph nodes-metastasis) or a
negative one. The concordant results were considered if
both Tg and body scans were positive (Tg+ and WBS+)
or both negative (Tg- and WBS-). Discordant results
were any other combination.
Results
In our 52 WBS+ patients concordant positive Tg lev-
els were observed in 42 patients (WBS+ and Tg+). In 10
patients we found a negative Tg levels and discordant re-
sults with WBS (WBS+ and Tg-) after the ablation dose
(Figure 1).
After 1 year follow-up, out of initially 42 concordant
patients 8 patients showed remaining conocordant posi-
tive Tg andWBS values (Tg+ andWBS+). Out of those 8
patients with concordant positive results 5 showed cervi-
cal remnants and in 3 patients distant metastasis were
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observed. Serum Tg levels were higher in patients with
distant metastasis (20-42 ng/mL) while in patients with
cervical remnants serum Tg levels were slightly above
the sensitivity level (3-5 ng/mL) (Table 1). Discordant re-
sults were observed in 13 patients (4 patients were
Tg-and WBS+ while 9 patients were Tg+ and WBS-).
Majority of the patients, 50% (21 patients) remained
with concordant results but changed from Tg+ and
WBS+ to Tg- and WBS- (Figure 2). All of the 10 initially
Tg- and WBS + patients remained Tg- after 1 year, out of
whom 8 converted to WBS- and 2 remained WBS+ (Fig-
ure 2).
Discussion
WBS+ Tg- has been documented in a small but signif-
icant number of cases9, 10. Muller-Gartner et al.13 re-
ported that false-negative serum Tg test results occurred
in patients with small papillary carcinoma with cervical
or mediastinal lymph node metastases and suggested
that the small tumor mass might account for undetect-
able Tg production. Mertens et al.10 presented the case of
a 54-y-old woman with metastatic follicular thyroid can-
cer and false-negative Tg. Many years after the patient
had a subtotal thyroidectomy, metastatic bone disease
was found. When the bone metastases were detected, se-
rum Tg values remained undetectable, whereas 131I WBS
demonstrated abundant uptake in the metastases during
the follow-up period. This case indicates that the combi-
nation of 131I scintigraphy and serum Tg values is supe-
rior to the measurement of serum Tg alone in detecting
DTC. The reliability of very low serum Tg-off levels (<3
ng/mL) was evaluated in 224 patients without Tg
Ab—who had undergone total thyroidectomy (125 pa-
tients) or thyroidectomy followed by 1 or more courses of
131I therapy (99 patients)—by performing WBS after a
therapeutic dose of 131I with Tg measurement at the
same time. WBS+ Tg- was found in 79 patients (35%). In
60 patients, the 131I uptake was limited to the thyroid
bed, but in 19 patients (8.5%), metastases were
demonstrated9. This study indicates that even serum
Tg-off is not a completely reliable method for follow-up of
DTC patients.
In our study, 52 WBS positive patients 42 (81%) also
had positive Tg levels, while false negative Tg results
were observed in 10 patients after the first therapeutic
dose. The possible causes of false-negative Tg might in-
clude low functional sensitivity of Tg methods to detect
small amounts of thyroid tissue when TSH is suppressed;
presence of Tg antibodies, immunologically inactive Tg
evades detection in a given Tg RIA. Tg produced by the
tumor contains unique epitopes and altered biochemical
features may obscure recognition by the antibodies used
in the assay12, which result in falsely low Tg values. The
dedifferentiated DTC cells can still concentrate iodine
but are unable to synthesize or release Tg. It was ob-
served that the least differentiated metastases are prone
to be associated with lower Tg levels. This could be ex-
plained by a decrease in the synthesis or release of a nor-
mal Tg and by the synthesis of an immunologically inert
Tg unrecognized by antibodies used in routine assays or
there is a more rapid clearance of Tg from the plasma9.
Iodine uptake is a prerequisite for 131I WBS diagnosis.
Loss of iodine uptake provides a reason for the DWBS-
that is observed frequently in metastasized DTC. As
many as 15% of DTC patients with an elevated Tg level
but a DWBS- are found on further evaluation to have
persistent, recurrent, or metastatic disease14. The possi-
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Fig. 1. Conocordant (WBS+Tg+) and discordant (WBS+Tg-)
results in the patients after the first therapheutic dose.
Fig. 2. Results of WBS and Tg serum levels after 1 year post total
thyroidectomy according to WBS and Tg concordance after initial
131I therapy. WBS- whole body scintigraphy; Tg-thyreoglobulin.
TABLE 1
PATIENTS WITH CONCORDANT AND DISCORDANT RESULTS 1
YEAR AFTER THE INITIAL TREATMANT
WBS+Tg+ WBS+Tg-
No of patients 8 9
Cervical remnants 5 6
Lymphatic nodes 2
Distant metastasis 3 1
WBS+Tg+ – positive 131I whole body scintigraphy and positive
serum thyreoglobulin test
WBS+Tg– – positive 131I whole body scintigraphy and negative
serum thyreoglobulin test
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ble causes might include: defective Iodine-Trapping
Mechanism, Loss of Differentiation, Dispersed Micro-
scopic Metastases, Improper Patient Preparation Before
131I WBS. Iodine uptake is an indicator of differentiated
behavior, as is the expression of sodium/iodine symporter
(NIS), Serum thyroid peroxidase (TPO), Tg, and TSH re-
ceptor. Any defect in them will contribute to false-nega-
tive 131I WBS. limitations in the detection of recurrent or
metastatic lesions occur when progressive
dedifferentiation of DTC cells leads to a loss of io-
dine-concentrating ability, but retaining the Tg synthe-
sizing capability, thereby becoming more difficult to
monitor and less responsive to traditional therapeutic
modalities15.
False-positive WBS occurs for a wide range of reasons,
including external contamination through saliva and
sweat, internal contamination through nasopharyngeal
secretion, as well as physiologic uptake in nonthyroidal
tissue such as choroid plexus, salivary glands, gastric
mucosa, and urinary tract. Shapiro et al.16 provide a logi-
cal classification and pathophysiologic interpretation of
the disparate literature of the host of artifacts, anatomic
and physiologic variants, and nonthyroidal diseases that
are responsible for false-positive 131I WBS, such as
ectopic foci of normal thyroid tissue; nonthyroidal physi-
ologic sites; contamination by physiologic secretions;
ectopic gastric mucosa; other gastrointestinal abnormali-
ties; urinary tract abnormalities; mammary abnormali-
ties; serous cavities and cysts; inflammation and infec-
tion; nonthyroidal neoplasms; and currently unexplained
causes. These cases of nonspecific131I accumulation make
more acute the urgency to be familiar with unusual but
possible causes that may mimic uptake by DTC
metastases15.
In our experience, the persistence of thyroid rem-
nants 1 year after surgery and therapeutic 131I dose was
high (total 19 patients remained WBS +, 36,5%). Out of
these 11 patients had undetectable Tg levels.
A major problem encountered during careful follow-
-up evaluations is the finding of a positive serum Tg con-
centration in a patient without demonstrable carcinoma
on the diagnostic WBS. It might be that the tumour can
trap 131I adequately but is too small to be visualised with
current diagnostic scanning procedures17. Although, as a
consequence, the tumour may be invisible on radioiodine
scanning, it may still produce enough Tg for serum de-
tection and sufficiently trap 131I for therapy. An aspect
that has come under consideration in recent years is
whether it is reasonable to use the presence of Tg in se-
rum as an indicator for 131I therapy when the diagnostic
WBS is negative. Schlumberger et al.17 report that 80%
of patients with a serum Tg-off level above 10 ng/ml will
have detectable 131I uptake in the neck or at distant sites
after the administration of a therapeutic activity of 131I;
in patients with a serum Tg-off level above 10 ng/mL and
a negative post-therapeutic scan, metastases may emer-
ge clinically some years later. The authors suggest a
Tg-off cut-off point of 10 ng/mL for 131I therapy without
prior diagnostic scan. If post-therapy uptake is noted,
they continue to treat the patient until the post-thera-
peutic WBS becomes negative. The authors state that
generally three cycles of 131I therapy (3,700 MBq per
therapy) are sufficient to reach this point. Early discov-
ery of metastases may permit a reduction in the cumula-
tive activity necessary for eradication of the tumour and
hence a reduction in total body irradiation. From a
dosimetric point of view, the relevant parameter is the
concentration of 131I in the tumour, i.e. the ratio between
131I uptake and mass of functioning tissue: a low uptake
in a small metastasis may result in a higher 131I concen-
tration than a higher uptake in a much larger metasta-
sis17. This means that it is reasonable to conclude that a
patient with a detectable Tg-off in combination with a
negative 123I WBS should be treated with a therapeutic
activity of 131I.
Conclusion
Based on our results, Tg as a solitary marker of thy-
roid remnant might give false negative results and there-
fore we suggest the diagnostic WBS as an additional
valuable armamentarium in the follow up of patients af-
ter total thyreoidectomy.
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ZNA^AJ SERUMSKOG TIREOGLOBULINA I SCINTIGRAFIJE CIJELOG TIJELA JODOM-131 U
PRA]ENJU PACIJENATA SA KARCINOMOM [TITNJA^E NAKON TIREOIDEKTOMIJE
S A @ E T A K
Serumski tireoglobulin (Tg) i scintigrafija cijelog tijela jodom-131 (131I SCT) se koriste u pra}enju recidiva i meta-
staza karcinoma {titnja~e u postoperativnom periodu. Objavljeni su opre}ni rezultati o koristnosti mjerenja Tg i 131I
SCT kod pacijenata sa karcinomom {titnja~e. Negativan 131I SCT nalaz i pozitivan serumski Tg se uo~avaju u najve}em
broju slu~ajeva, ali je pozitivan nalaz 131I SCT i negatian Tg test prisutan u manjem, ali zna~ajnom, broju slu~ajeva.
Stoga je cilj studije bio da se retrospektivno analiziraju slu~ajevi pacijenata sa pozitivnim 131I SCT nalazom nakon
totalne tireoidektomije i ponovo 1 godinu nakon terapije radioaktivnim jodom. U studiju je bilo uklju~eno ukupno 52
pacijenta. Svaki pacijent je primio ablativnu dozu 131I tokom 4 sedmice postoperativno bez uvo|enja tireoidne supsti-
tucione terapije. Evaluacije SCT je bila kvalitativna i nalaz je smatran pozitivan ukoliko su uo~eni: ostatno tkivo {titne
`lijezde, limfni ~vorovi ili matastaze (SCT+). SCT i serumski Tg je mjeren 12 mjeseci nakon ablacije sa 131I. Tg test je
smatran pozitivan (Tg+) ukoliko je serumski Tg bio iznad donje granice senzitivnosti. Nivo Tg u serumu je upore|ivan
sa nalazom SCT. Od ukupno 52 SCT+ pacijenta, njih 42 su imali i pozitivan serumski Tg, dok je 10 pacijenata imalo
negativan Tg test postoperativno. Nakon 1-godi{njeg perioda pra}enja, od inicijalnih 42 Tg+ i SCT+ pacijenta,
utvr|eno je da je 8 pacijenata i dalje imalo pozitivan i Tg i SCT test, dok su se kod 13 pacijenata uo~ili opre~ni rezultati
(4 pacijenta su bila Tg-i SCT+ dok je 9 pacijenata imalo Tg+ i SCT-). Kod ve}ine pacijenata u studiji (50%) utvr|eni su
konkordantni rezultati Tg i SCT testa, s tim da su inicijalno pacijenti sa pozitivnim Tg testom i SCT nalazom nakon 1
godine imali negativan i Tg test i SCT nalaz. Dijagnosti~ki SCT je pored Tg testa, dodatna zna~ajna pretraga u pra}enju
pacijenata nakon totalne tireoidektomije.
E. Ku~ukali}-Selimovi} et al.: Thyreoglobulin and Body Scintigraphy after Thyroidectomy, Coll. Antropol. 36 (2012) Suppl. 2: 67–71
71
U:\coll-antropolo\coll-antro-(Suppl 2)-2012\41 Kucukalic.vp
20. studeni 2012 13:58:40
Color profile: Generic CMYK printer profile
Composite  150 lpi at 45 degrees
